Clinical Trial Update: Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 trial evaluating low-dose interleukin-2 in combination with pembrolizumab for stage IV non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Proleukin (aldesleukin)

Snippet

Sponsor: Emory University | Conditions: Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | EARLY_Phase 1 | Status: RECRUITING